Navigation Links
Yew Bio-Pharm Group Reports 2015 Second Quarter Financial Results
Date:8/18/2015

HARBIN, China, Aug. 18, 2015 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for three- and six-months ended June 30, 2015.

2015 Second Quarter ResultsThree Months Ended June 30,Percentage2015

2014ChangeRevenues:TCM Raw Materials

$3,909,313

$1,150,855

240%Yew Trees

344,919

872,437

(60)%Wood ear mushroom

405,484

-

100%Handicrafts

7,206

40,325

(82)%Total Revenues

$4,666,922

$2,063,527

126% 

Total revenues for the second quarter of 2015 increased 126% to $4.7 million from $2.1 million a year ago. Sales of TCM raw materials amounted to 83.8% of total revenues; sales of yew trees amounted to 7.4% of total revenues; sales of wood ear mushroom amounted to 8.7% of total revenues; and sales of handicrafts made up the remaining 0.1%.

For the 2015 second quarter, gross profit was $2.4 million, or 51% of total revenues, compared with $1.6 million, or 79.4% of total revenues for the comparable 2014 quarter. The decrease in the gross profit margin was primarily attributable to the lower gross margin yield of wood ear mushroom segment, and a one-time yew tree extracts sales occurred in June, 2015.

Operating expenses increased 119% to $484,475 for the quarter ended June 30, 2015, from $221,022 in the year-ago quarter. The increasing was primarily attributable to the increases in compensation and related benefits and other expenses.

Net income for the three months ended June 30, 2015 increased 41% to $2,005,656 from $1.4 million in the same quarter last year due to the increases of total revenues. Earnings per diluted share for the three months ended June 30, 2015 was $0.03, in line with the same period last year.

Six Month 2015 Financial ResultsSix Months Ended June 30,Percentage2015

2014ChangeRevenues:TCM Raw Materials

$4,866,320

$2,194,785

122%Yew Trees

1,043,671

1,836,743

(43)%Wood ear mushroom

1,304,672

-

100%Handicrafts

94,714

100,016

(5)%Total Revenues

$7,309,377

$4,131,544

77% 

Total revenues for the first six months of 2015 increased to $7.3 million from $4.1 million a year ago. Sales of TCM raw materials amounted to 66.6% of total revenues; sales of yew trees amounted to 14.3% of total revenues; sales of wood ear mushroom amounted to 17.8% of total revenues; and sales of handicrafts made up the remaining 1.3%.

Gross profit was $3.9 million, or 52.7% of total revenues, compared with $3.2 million, or 77.0% of total revenues for the comparable 2014 quarter. The decrease in the gross profit margin was primarily attributable to the lower gross margin yield of wood ear mushroom segment, and the one-time yew tree extracts sales occurred in June, 2015

Operating expenses increased 146% to $956,541 for the six months ended June 30, 2015, from $388,418 for the same period last year. The increasing was primarily attributable to the increases in compensation and related benefits and other expenses.

Net income for the first six months of 2015 increased 6% to $3.0 million from $2.8 million for the same period last year. Earnings per diluted share were $0.05, compared to $0.04 for the same period last year.

At June 30, 2015 the company had approximately $610,000 in cash and $3.2 million in accounts receivable.

"Revenue for the quarter increased 126% compared to last year due to the sales increases in TCM raw materials and wood ear mushroom segments which offset the decrease of Yew tree sales," said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group, Inc. " Wood ear mushroom sales contributed a large proportion for the Company's revenues in the past half year, and we expect to develop more customer resources and expand our wood ear mushroom sales in the next half of 2015."

"Our TCM raw materials sales increased sharply in the second quarter of 2015 which was mainly due to the increase in demand from our related party, Yew Pharmaceutical. Yew Pharmaceutical has developed a new technology to extract yew essence oil from TCM raw materials and further processing the oil to be used as the base of a new product, Yew Candle. The development of Yew Candle had led to the increase in demand of TCM raw materials. Sales of Yew Candle would begin in early October this year, and we expect our TCM raw materials sales will continue to increase."

ABOUT YEW BIO-PHARM GROUP, INCYew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. Yew Bio-Pharm also recently established a division to focus on organic foods and dietary supplements with the aim of developing new business opportunities in related industries. To learn more, please visit www.yewbiopharm.com.

SAFE HARBORThis press release forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.  These forward-looking statements involve a number of risks and uncertainties that could cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.  A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our ability to collect from our largest customers; our dependence on a small number of customers for raw materials, including a related party; our ability to continue to purchase raw materials at relatively stable prices; our dependence on a small number of customers for our yew trees for reforestation; our ability to market successfully raw materials used in the manufacture of traditional Chinese medicines; and our ability to receive continued preferential tax treatment for the sale of yew trees and potted yew trees.  From time to time, these risks, uncertainties and other factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K.  Yew Bio does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law.

Investor Relations Contacts:
Cami Xue
Chineseinvestors.com, Inc.
Tel: (800) 958-8561
Cami@chinesefn.com

 

(financial tables follow)YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSJune 30,
2015December 31,
2014(Unaudited)ASSETSCURRENT ASSETS:Cash$

610,658$

487,940Accounts receivable2,236,486922,564Accounts receivable - related party975,562340,132Inventories3,509,4141,443,078Prepaid expenses - related party126,7315,787Prepaid expenses and other assets2,003,90616,791Total Current Assets9,462,7573,216,292LONG-TERM ASSETS:Long-term inventories, net11,083,44610,663,545Property and equipment, net795,544856,250Land use rights and yew forest assets, net20,574,88320,305,821Total Long-term Assets32,453,87331,825,616Total Assets$

41,916,630$

35,041,908LIABILITIES AND SHAREHOLDERS' EQUITYCURRENT LIABILITIES:Accounts payable$

427,165$

-Accrued expenses and other payables268,14184,722Advances from customers67,501-Taxes payable16,44410,547Due to related parties697,44545,040Short-term borrowings1,642,360-Total Current Liabilities3,119,056140,309Total Liabilities3,119,056140,309SHAREHOLDERS' EQUITY:Common stock ($0.001 par value; 140,000,000 shares authorized; 52,125,000 shares issued and outstanding at June 30, 2015 and December 31, 2014)52,12552,125Additional paid-in capital9,108,0388,557,656Retained earnings23,043,44020,444,667Statutory reserves3,466,0393,100,766Accumulated other comprehensive income - foreign currency translation adjustment3,127,9322,746,385Total Shareholders' Equity38,797,57434,901,599Total Liabilities and Shareholders' Equity$

41,916,630$

35,041,908 YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME(UNAUDITED)For the Three Months Ended
June 30,For the Six Months Ended
June 30,2015201420152014REVENUES:Revenues$

1,904,941$

1,780,535$

3,439,595$

3,394,253Revenues - related party2,761,981283,0323,869,782737,291Total Revenues4,666,9222,063,5677,309,3774,131,544COST OF REVENUES:Cost of revenues1,533,314354,4561,907,359769,072Cost of revenues - related party753,80670,4791,550,730183,597Total Cost of Revenues2,287,120424,9353,458,089952,669GROSS PROFIT2,379,8021,638,6323,851,2883,178,875OPERATING EXPENSES:Selling9,07566113,7632,421General and administrative475,400220,361942,778385,997Total Operating Expenses484,475221,022956,541388,418INCOME FROM OPERATIONS1,895,3271,417,6102,894,7472,790,457OTHER INCOME (EXPENSES):Interest income (expense)(18,546)55(18,421)291Government grant135,322-135,322-Other income (expense)(4,457)(194)(4,473)1,964Total Other Income (Expenses)112,319(139)112,4282,255INCOME BEFORE INCOME TAXES2,007,6461,417,4713,007,1752,792,712PROVISION FOR INCOME TAXES(1,990)-(43,129)-NET INCOME$

2,005,656$

1,417,471$

2,964,046$

2,792,712COMPREHENSIVE INCOME:NET INCOME$

2,005,656$

1,417,471$

2,964,046$

2,792,712OTHER COMPREHENSIVE INCOME (LOSS):Foreign currency translation adjustment123,69435,482381,547(222,486)COMPREHENSIVE INCOME$

2,129,350$

1,452,953$

3,345,593$

2,570,226NET INCOME PER COMMON SHARE:Basic$

0.04$

0.03$

0.06$

0.06Diluted$

0.03$

0.03$

0.05$

0.04WEIGHTED AVERAGE COMMON SHARES

OUTSTANDING:Basic52,125,00050,000,00052,125,00050,000,000Diluted57,618,68950,000,00057,899,66964,872,148 YEW BIO-PHARM GROUP, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)For the Six Months Ended
June 30,20152014CASH FLOWS FROM OPERATING ACTIVITIES:Net income$

2,964,046$

2,792,712Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation76,09991,862Stock-based compensation537,660-Stock issued for professional services12,722-Amortization of land use rights and yew forest assets256,333255,678Gain on disposal of property and equipment-(2,142)Changes in operating assets and liabilities:Accounts receivable(1,300,729)(911,790)Accounts receivable - related party(629,335)237,626Prepaid expenses and other current assets(1,979,257)(20,473)Prepaid expenses - related party(120,407)-Due from related parties-14,034Inventories(2,071,367)358,413Accounts payable427,05842,398Accrued expenses and other payables182,092(1,100)Advances from customers67,236-Taxes payable5,789(3,865)NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES(1,572,060)2,853,353CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from disposal of property and equipment-5,000Purchase of property and equipment(7,000)-Payment for land use rights and yew forest assets(588,928)(3,755,629)NET CASH USED IN INVESTING ACTIVITIES(595,928)(3,750,629)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from short-term borrowings1,642,360-Proceeds from related party advances652,3631,221Repayments for related party advances-(25,674)NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES2,294,723(24,453)EFFECT OF EXCHANGE RATE ON CASH(4,017)(7,204)NET INCREASE (DECREASE) IN CASH122,718(928,933)CASH - Beginning of period487,9401,159,611CASH - End of period$

610,658$

230,678SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Cash paid for:Interest$

18,647$

-Income taxes$

-$

-Non-cash investing and financing activitiesReclassification of yew forest assets to inventories$

279,514$

1,658 

 


'/>"/>
SOURCE Yew Bio-Pharm Group, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
2. Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
3. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
4. Yew Bio-Pharm Welcomes Two New Board Members
5. Yew Bio-Pharm Group Reports 2014 Second Quarter Financial Results
6. Yew Bio-Pharm Signs Exclusive Distribution Agreement with Carpal Aid to Market Carpal Tunnel Syndrome Product in China
7. Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results
8. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
9. Hemp, Inc. Signs Letter of Intent with One of Chinas Largest Agricultural Producers, Yasheng Group
10. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
11. Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):